Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
33 NC counties and 1 VA county are under alert, including Wake, Cumberland, Durham, Johnston, and Orange counties.
Just In
WRAL Weather Alert Day: Several downed trees reported along I-40 westbound in Wake County as storms move through central NC
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vir Biotechnology Inc
(NQ:
VIR
)
8.620
-0.040 (-0.46%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vir Biotechnology Inc
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Breaking Down Vir Biotechnology: 6 Analysts Share Their Views
August 02, 2024
Via
Benzinga
VIR Stock Earnings: Vir Biotechnology Misses EPS, Misses Revenue for Q2 2024
August 01, 2024
VIR stock results show that Vir Biotechnology missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities
August 01, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers
August 01, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Evaluating Vir Biotechnology: Insights From 5 Financial Analysts
May 24, 2024
Via
Benzinga
Deep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings)
May 07, 2024
Via
Benzinga
Assessing Vir Biotechnology: Insights From 5 Financial Analysts
March 15, 2024
Via
Benzinga
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
July 26, 2024
On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier.
Via
Investor's Business Daily
Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024
July 18, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
July 04, 2024
These three undervalued biotech stocks have begun garnering investor attention as their treatments show promise.
Via
InvestorPlace
Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection
June 26, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday?
June 05, 2024
Vir Biotechnology reports promising Phase 2 SOLSTICE hepatitis delta trial results, showing high virologic response and ALT normalization rates with tobevibart and elebsiran.
Via
Benzinga
Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
June 05, 2024
Via
Benzinga
Ollie's Bargain Outlet Posts Upbeat Earnings, Joins Verint Systems, Guidewire Software And Other Big Stocks Moving Higher On Wednesday
June 05, 2024
Via
Benzinga
Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment
June 05, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
May 29, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
May 29, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Host 2024 Annual Meeting of Stockholders
May 23, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
May 22, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
May 21, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
VIR Stock Earnings: Vir Biotechnology Beats EPS for Q1 2024
May 02, 2024
VIR stock results show that Vir Biotechnology beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 02, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024
April 30, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors
April 18, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
April 11, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
March 19, 2024
These biotech stocks to buy offer a gateway to long-term gains, on the back of groundbreaking healthcare innovations.
Via
InvestorPlace
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
March 13, 2024
One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses.
Via
InvestorPlace
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
March 05, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
3 Highly Rated Biotech Stocks to Buy for 300% Gains
February 26, 2024
Biotech stocks like those discussed here have the potential to produce 300% returns and benefit from high analyst ratings.
Via
InvestorPlace
Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
February 23, 2024
Shares of MercadoLibre, Inc. (NASDAQ: MELI) fell sharply during Friday’s session after the company reported fourth-quarter financial results.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.